actual results and the implementation of the Company's plans to vary materially, including the risks associated with 
the initiation, cost, timing, progress and results of the Company's current and future research and development 
activities and preclinical studies and clinical trials. These risks are discussed in the Company's filings with the 
U.S. Securities and Exchange Commission (SEC), including, without limitation, the Company's Annual Report on Form 10-K 
filed on March 15, 2021 and the Company's subsequent filings with the SEC. Except as required by law, the Company 
assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in 
the future. 
Media Contacts: 
Bill Berry 
Berry & Company Public Relations 
W: 212-253-8881 
C: 917-846-3862 
bberry@berrypr.com 
 
Jenna Urban 
Berry & Company Public Relations 
W: 212-253-8881 
C: 203-218-9180 
jurban@berrypr.com 
 
Investor Contacts: 
Matt Lane 
Gilmartin Group 
617-901-7698 
matt@gilmartinir.com 
 
 
=---------------------------------------------------------------------------------------------------------------------- 
ISIN:           GB00BD045071 
Category Code:  MSCM 
TIDM:           ARIX 
LEI Code:       213800OVT3AHQCXNIX43 
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State 
Sequence No.:   100691 
EQS News ID:    1188591 
 
End of Announcement  EQS News Service 
=------------------------------------------------------------------------------------
 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1188591&application_name=news

(END) Dow Jones Newswires

April 27, 2021 09:00 ET (13:00 GMT)